Compartir

We expand our FATs capabilities

 In Bionet News
1046

We have expanded our FAT (Factory Acceptance Test) capabilities! At BIONET, we have invested heavily to expand our utilities (steam, compressed air & cooling water) at the back-stage of our facilities.

This enables us to fully perform tests on bioreactors of working volume above 3,000 L as well as complete bioproduction lines before shipping. WE ALL WIN! Our clients can have the certainty that we deliver what we promised before shipping to site, while we can reduce the risks at SATs. This new utilities will also increase the quality of services provided at our Pilot Plant, including the development of Downstream processes.

Recent Posts
  • Bionet News

    Proyecto AD-VISOR

    “VALORIZACIÓN INTEGRAL DE SUBPRODUCTOS ANIMALES PARA LA PRODUCCIÓN DE BIOPLÁSTICOS Y BIOMETANO” El objetivo general del proyecto AD-VISOR es el desarrollo de un sistema de valorización integral de residuos cárnicos y subproductos animales no destinados a consumo humano (SANDACH) en el entorno de una EDAR para la producción de bioplásticos (polihidroxialcanoatos de cadena media o mcl-PHA) y de biometano como combustible vehicular. Expediente – 00111839/ ITC-20181179 Lugar de ejecución: Guijuelo (SALAMANCA) Plazo de ejecución del 01/10/2018 al 31/12/2020 Presupuesto Total: 1.379.151,00 €    Este proyecto ha sido cofinanciado por el […]

    See more >

  • Bionet News

    BIONET’s contribution to Europe’s R&D

    BIONET is taking part in the EU funded project GreenProtein. The GreenProtein project aims at producing high-added value, food-grade and fully functional proteins and other food ingredients, out of vegetable residues from the packed salad processing. Our role within the project is a crucial one, consisting on the scale-up of the process and the translation between the process needs and user requirements into the design and construction of technological capacities. The project started on September 2016 will last 4,5 years and gathers nine partners from 5 different countries. GreenProtein is […]

    See more >

  • Bionet News

    CDTI, BIONET Y UN BIOREACTOR DE VACUNAS

    “Desarrollo de un bioreactor avanzado para mejorar la productividad y flexibilidad en la fabricación de vacunas”   Resumen y objetivos   Desarrollar las tecnologías necesarias para crear un Bioreactor específico para la fabricación de vacunas que mejore la productividad y flexibilidad de los sistemas existentes en el mercado. Se trata de tratar de mejorar claves para el usuario en la fabricación de vacunas como:   Productividad mediante la mejora de los procesos y automatización avanzada que reduzca costes Flexibilidad, permitiendo producir en los mismos equipos una amplia gama de productos […]

    See more >

  • Bionet News

    BIONET CONTINUES ITS CONSOLIDATION AS A LEADER IN THE SUPPLY OF COMPLETE BIOPRODUCTION FACILITIES

    In Bionet’s trajectory a lot of the work and expertise has been developed around industrial scale projects, and 2017 has been a great year for this, with bioproduction plants put in place by Bionet for clients working in the monoclonal antibodies, animal vaccine and biocide production fields in three different European countries. As a representative example, Bionet has had the opportunity to be the supplier of a Microbial Upstream Pilot Plant for the production of a monoclonal antibody for the biopharma division of Polpharma Group, one of the largest pharmaceutical companies in Central and Eastern Europe company based […]

    See more >

Start typing and press Enter to search

Like any other website, we use our own and third-party cookies so that everything works correctly, by continuing with your visit you accept the use of cookies for statistical purposes. More info

Los ajustes de cookies de esta web están configurados para "permitir cookies" y así ofrecerte la mejor experiencia de navegación posible. Si sigues utilizando esta web sin cambiar tus ajustes de cookies o haces clic en "Aceptar" estarás dando tu consentimiento a esto.

Cerrar